Table 2 Treatment-related adverse events
Grades 1/2 | Grade 3 | Grades 4/5 | All grades (%) | ≥Grade 3 (%) | |
|---|---|---|---|---|---|
Hematologic AEs | |||||
Overall | 94.4 | 33.3 | |||
Leucopenia | 14 | 1 | 0 | 41.7 | 2.8 |
Neutropenia | 12 | 7 | 1 | 55.6 | 22.2 |
Anemia | 27 | 2 | 0 | 80.5 | 5.6 |
Thrombocytopenia | 19 | 2 | 0 | 58.3 | 5.6 |
Non-hematologic AEs | |||||
Elevated AST | 11 | 0 | 0 | 30.5 | 0 |
Elevated ALT | 6 | 0 | 0 | 16.7 | 0 |
Hyperbilirubinemia | 2 | 0 | 0 | 5.6 | 0 |
Fatigue | 7 | 3 | 0 | 27.8 | 8.3 |
Anorexia | 9 | 2 | 0 | 27.8 | 5.6 |
Nausea | 4 | 0 | 0 | 11.1 | 0 |
Vomiting | 3 | 1 | 0 | 11.1 | 2.8 |
Diarrhea | 4 | 2 | 0 | 16.7 | 5.6 |
Stomatitis | 5 | 0 | 0 | 11.1 | 0 |
Hand–foot syndrome | 18 | 3 | 0 | 58.3 | 8.3 |
Injection site reaction | 3 | 0 | 0 | 8.3 | 0 |
Neuropathy (sensory) | 25 | 5 | 0 | 83.3 | 13.9 |
Allergy | 2 | 0 | 0 | 5.6 | 0 |
Bevacizumab-associated AEs | |||||
Hypertension | 6 | 4 | 0 | 27.8 | 11.1 |
Proteinuria | 11 | 2 | 0 | 36.1 | 5.6 |
Thrombosis | 0 | 1 | 0 | 2.8 | 2.8 |
Bleeding | 1 | 1 | 1 | 8.3 | 5.6 |